Patents by Inventor Lucy Xiumin Zhao

Lucy Xiumin Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzoimidazoles as prolyl hydroxylase inhibitors
    Patent number: 11618744
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: April 4, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, Jr., Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS
    Publication number: 20210078978
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Application
    Filed: November 24, 2020
    Publication date: March 18, 2021
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, JR., Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • Benzoimidazoles as prolyl hydroxylase inhibitors
    Patent number: 10851083
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: December 1, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, Jr., Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • POLYMERIC TANDEM DYES HAVING PENDANT NARROW EMISSION ACCEPTOR
    Publication number: 20200048469
    Abstract: Polymeric tandem dyes are provided. The polymeric tandem dyes include a narrow emission fluorophore configured as a pendant acceptor in energy-receiving proximity to a donor water solvated light harvesting multichromophore. The narrow emission acceptor fluorophores of the present disclosure are capable of providing polymeric tandem dyes having a variety of narrow emission spectrums suitable for multiplexing. Also provided are compositions for multicolor fluorescent signal generation that include two or more polymeric tandem dyes. Methods of evaluating a sample for the presence of a target analyte and methods of labelling a target molecule in which the subject polymeric dyes find use are also provided. Systems and kits for practicing the subject methods are also provided.
    Type: Application
    Filed: July 26, 2019
    Publication date: February 13, 2020
    Inventors: Glenn Bartholomew, Yongchao Liang, Lucy Xiumin Zhao
  • BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS
    Publication number: 20190367486
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Application
    Filed: March 7, 2019
    Publication date: December 5, 2019
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, JR., Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS
    Publication number: 20180215732
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Application
    Filed: September 5, 2017
    Publication date: August 2, 2018
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS
    Publication number: 20180022733
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Application
    Filed: September 5, 2017
    Publication date: January 25, 2018
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS
    Publication number: 20160168127
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Application
    Filed: December 14, 2015
    Publication date: June 16, 2016
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis
    Publication number: 20160158307
    Abstract: The present invention provides a family of novel cytotoxic pentapeptides, which show potent antitumor activities against several cancer lines. The antibody-drug conjugates prepared from those pentapeptides can efficiently kill cancer cells.
    Type: Application
    Filed: February 15, 2016
    Publication date: June 9, 2016
    Applicant: ACES Pharma Inc.
    Inventors: Shanghui Hu, Lucy Xiumin Zhao, Jinying Ning, Xufang Tian, Chao Li, Wei Hu, Xu Liu, Bonnie Y. Hu
  • Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis
    Patent number: 9260478
    Abstract: The present invention provides a family of novel cytotoxic pentapeptides, which show potent antitumor activities against several cancer lines. The antibody-drug conjugates prepared from those pentapeptides can efficiently kill cancer cells.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: February 16, 2016
    Inventors: Shanghui Hu, Lucy Xiumin Zhao, Jinying Ning, Xufang Tian
  • Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis
    Publication number: 20150284425
    Abstract: The present invention provides a family of novel cytotoxic pentapeptides, which show potent antitumor activities against several cancer lines. The antibody-drug conjugates prepared from those pentapeptides can efficiently kill cancer cells.
    Type: Application
    Filed: October 16, 2014
    Publication date: October 8, 2015
    Applicant: ACES Pharma Inc.
    Inventors: Shanghui Hu, Lucy Xiumin Zhao, Jinying Ning, Xufang Tian
  • Benzoimidazoles as prolyl hydroxylase inhibitors
    Publication number: 20150284335
    Abstract: Certain Benzoimidazole compounds are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., Anemia, vascular disorders, metabolic disorders, and wound healing.
    Type: Application
    Filed: June 5, 2015
    Publication date: October 8, 2015
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, JR., Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • Benzoimidazoles as prolyl hydroxylase inhibitors
    Patent number: 9073923
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: July 7, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, Jr., Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • Benzoimidazoles as prolyl hydroxylase inhibitors
    Patent number: 8865713
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: October 21, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, Jr., Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS
    Publication number: 20140256722
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Application
    Filed: May 20, 2014
    Publication date: September 11, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Frances Meredith HOCUTT, Barry Eastman Leonard, JR., Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • Benzoimidazoles as prolyl hydroxylase inhibitors
    Patent number: 8759345
    Abstract: The present invention is directed to benzoimidazole compounds of the formula (1) and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: June 24, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, Jr., Hillary M Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS
    Publication number: 20140005193
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Application
    Filed: September 3, 2013
    Publication date: January 2, 2014
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Frances Meredith Hocutt, BARRY EASTMAN LEONARD, JR., HILLARY M. PELTIER, VICTOR K. PHUONG, MICHAEL H. RABINOWITZ, MARK D. ROSEN, KYLE T. TARANTINO, HARIHARAN VENKATESAN, LUCY XIUMIN ZHAO
  • BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS
    Publication number: 20110046132
    Abstract: The present invention is directed to benzoimidazole compounds of the formula (1) and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Application
    Filed: April 28, 2009
    Publication date: February 24, 2011
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, JR., Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao